Over 50% of ankylosing spondylitis patients treated with anti-tumour necrosis factor show a 50% improvement Infliximab, etanercept (and probably adalimumab) are equally effective Stable responses are maintained for two years If treatment is discontinued, almost all patients relapse Retreatment is probably as effective as initial treatment Pre-test screening for tuberculosis is essential The overall risk to benefit ratio is favourable.
机构:
Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, SE-17176 Stockholm, SwedenKarolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden
Askling, Johan
Dixon, Will
论文数: 0引用数: 0
h-index: 0
机构:
Univ Manchester, Epidemiol Unit, Manchester, Lancs, EnglandKarolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden